MX2018004016A - Vacunas de particulas tipo virus (vlp) contra el parvovirus canino (cpv) y sus usos. - Google Patents

Vacunas de particulas tipo virus (vlp) contra el parvovirus canino (cpv) y sus usos.

Info

Publication number
MX2018004016A
MX2018004016A MX2018004016A MX2018004016A MX2018004016A MX 2018004016 A MX2018004016 A MX 2018004016A MX 2018004016 A MX2018004016 A MX 2018004016A MX 2018004016 A MX2018004016 A MX 2018004016A MX 2018004016 A MX2018004016 A MX 2018004016A
Authority
MX
Mexico
Prior art keywords
cpv
vlp
vaccines
particle
virus
Prior art date
Application number
MX2018004016A
Other languages
English (en)
Inventor
David Frederic
Hannas-Djebbara Zahia
Poulet Herve
Maarten Minke Jules
Original Assignee
Merial Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merial Inc filed Critical Merial Inc
Publication of MX2018004016A publication Critical patent/MX2018004016A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/125—Picornaviridae, e.g. calicivirus
    • A61K39/135—Foot- and mouth-disease virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/23—Parvoviridae, e.g. feline panleukopenia virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14311—Parvovirus, e.g. minute virus of mice
    • C12N2750/14323—Virus like particles [VLP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14311—Parvovirus, e.g. minute virus of mice
    • C12N2750/14334—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14311—Parvovirus, e.g. minute virus of mice
    • C12N2750/14371—Demonstrated in vivo effect
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/32011—Picornaviridae
    • C12N2770/32111—Aphthovirus, e.g. footandmouth disease virus
    • C12N2770/32123—Virus like particles [VLP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/32011—Picornaviridae
    • C12N2770/32111—Aphthovirus, e.g. footandmouth disease virus
    • C12N2770/32134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Organic Chemistry (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

Vacunas o composiciones contra el parvovirus canino (CPV). La vacuna o composición puede ser una vacuna o composición que contiene una partícula tipo virus (VLP) del CPV y un método de preparación y un uso de la misma. Las VLP del CPV provistas por la invención están formadas por la proteína VP2 del CPV. Además, la invención abarca en general vacunas que comprenden combinaciones de MLV y VLP, que tienen la capacidad para neutralizar las MDA contra una variedad de patógenos, que infectan numerosas especies diferentes.
MX2018004016A 2015-09-29 2016-09-14 Vacunas de particulas tipo virus (vlp) contra el parvovirus canino (cpv) y sus usos. MX2018004016A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562234196P 2015-09-29 2015-09-29
PCT/US2016/051736 WO2017058521A1 (en) 2015-09-29 2016-09-14 Canine parvovirus (cpv) virus-like particle (vlp) vaccines and uses thereof

Publications (1)

Publication Number Publication Date
MX2018004016A true MX2018004016A (es) 2018-11-29

Family

ID=57003591

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018004016A MX2018004016A (es) 2015-09-29 2016-09-14 Vacunas de particulas tipo virus (vlp) contra el parvovirus canino (cpv) y sus usos.

Country Status (24)

Country Link
US (2) US10080798B2 (es)
EP (2) EP4286002A3 (es)
JP (1) JP6818748B2 (es)
CN (1) CN108348594B (es)
AR (1) AR106026A1 (es)
AU (1) AU2016332037B2 (es)
BR (1) BR112018006567A2 (es)
CA (1) CA3000352A1 (es)
CL (1) CL2018000820A1 (es)
CO (1) CO2018003460A2 (es)
DK (1) DK3355915T3 (es)
FI (1) FI3355915T3 (es)
HR (1) HRP20231630T1 (es)
LT (1) LT3355915T (es)
MA (1) MA43016A (es)
MX (1) MX2018004016A (es)
NZ (1) NZ741875A (es)
PL (1) PL3355915T3 (es)
PT (1) PT3355915T (es)
RS (1) RS65084B1 (es)
RU (1) RU2710854C1 (es)
SI (1) SI3355915T1 (es)
WO (1) WO2017058521A1 (es)
ZA (1) ZA201802117B (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6818748B2 (ja) * 2015-09-29 2021-01-20 ベーリンガー インゲルハイム アニマル ヘルス ユーエスエイ インコーポレイテッド イヌパルボウイルス（ｃｐｖ）ウイルス様粒子（ｖｌｐ）ワクチン及びその使用
US11730805B2 (en) 2017-09-23 2023-08-22 Boehringer Ingelheim Vetmedica Gmbh Paramyxoviridae expression system
CN108273055A (zh) * 2018-01-03 2018-07-13 复旦大学 犬细小病毒疫苗组合物及其制备方法与应用
KR102117810B1 (ko) * 2018-11-29 2020-06-02 대한민국(농림축산식품부 농림축산검역본부장) 재조합 개파보바이러스 2c 항원 단백질 및 이의 용도
CN110157687A (zh) * 2019-05-25 2019-08-23 青岛易邦生物工程有限公司 一种犬细小病毒三价亚单位疫苗
EP4277654A1 (en) 2021-01-18 2023-11-22 Conserv Bioscience Limited Coronavirus immunogenic compositions, methods and uses thereof
CN114317459B (zh) * 2021-12-31 2024-02-23 长春西诺生物科技有限公司 一种犬瘟热病毒株和基于犬瘟热病毒和犬细小病毒的二联疫苗及应用
CN114957406B (zh) * 2022-05-26 2024-02-02 吉林大学 一种犬细小病毒的三价抗原和三价病毒样颗粒以及应用
CN116376981A (zh) * 2023-04-21 2023-07-04 西北农林科技大学 一种重组犬细小病毒假病毒

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2909462A (en) 1955-12-08 1959-10-20 Bristol Myers Co Acrylic acid polymer laxative compositions
US5505941A (en) 1981-12-24 1996-04-09 Health Research, Inc. Recombinant avipox virus and method to induce an immune response
EP0138854B1 (en) 1983-03-08 1992-11-04 Chiron Mimotopes Pty. Ltd. Antigenically active amino acid sequences
EP0173552B1 (en) 1984-08-24 1991-10-09 The Upjohn Company Recombinant dna compounds and the expression of polypeptides such as tpa
US5168062A (en) 1985-01-30 1992-12-01 University Of Iowa Research Foundation Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence
US4968615A (en) 1985-12-18 1990-11-06 Ciba-Geigy Corporation Deoxyribonucleic acid segment from a virus
US4963481A (en) 1985-12-18 1990-10-16 Genetics Institute Inc Promoter system
DK175363B1 (da) 1986-09-12 2004-09-13 Genentech Inc Fremgangsmåde til kontinuert produktion af et önsket heterologt protein i en eukaryotisk værtcelle, vektor, som tilförer denne evne, og celler transformeret med vektoren
GB8717430D0 (en) 1987-07-23 1987-08-26 Celltech Ltd Recombinant dna product
DE3743138A1 (de) 1987-12-18 1989-09-14 Mayr Christian Gmbh & Co Kg Schleifringlose, elektromagnetische ueberlastkupplung
US4971793A (en) 1988-05-09 1990-11-20 Boyce Thompson Institute For Plant Research, Inc. Subunit canine parvovirus vaccine
US6204044B1 (en) 1989-09-14 2001-03-20 Caroline Sarah Brown Human parvovirus B19 proteins and virus-like particles, their production and their use in diagnostic assays and vaccines
KR100242671B1 (ko) 1991-03-07 2000-03-02 고돈 에릭 유전학적으로 처리한 백신 균주
EP0826063A1 (en) 1995-04-25 1998-03-04 Vical Incorporated Single-vial formulations of dna/lipid complexes
US5846946A (en) 1996-06-14 1998-12-08 Pasteur Merieux Serums Et Vaccins Compositions and methods for administering Borrelia DNA
FR2751225B1 (fr) 1996-07-19 1998-11-27 Rhone Merieux Formule de vaccin polynucleotidique aviaire
FR2751227B1 (fr) 1996-07-19 1998-11-27 Rhone Merieux Formule de vaccin polynucleotidique contre les pathologies canines, notamment les pathologies respiratoires et digestives
FR2751228B1 (fr) 1996-07-19 1998-11-20 Rhone Merieux Vaccin polynucleotidique bovin pour voie intradermique
FR2751226B1 (fr) 1996-07-19 1998-11-27 Rhone Merieux Formule de vaccin polynucleotidique contre les pathologies du cheval
FR2751229B1 (fr) 1996-07-19 1998-11-27 Rhone Merieux Formule de vaccin polynucleotidique notamment contre la pathologie respiratoire des bovins
FR2751224B1 (fr) 1996-07-19 1998-11-20 Rhone Merieux Formule de vaccin polynucleotidique contre les pathologies respiratoires et de reproduction des porcs
ES2241042T3 (es) 1996-10-11 2005-10-16 The Regents Of The University Of California Conjugados de polinucleotido inmunoestimulador/ molecula inmunomoduladora.
CA2223029A1 (en) 1997-02-12 1998-08-12 Akzo Nobel Nv Canine parvovirus dna vaccines
CN1261807A (zh) 1997-06-30 2000-08-02 罗纳-布朗克罗莱尔股份有限公司 向横纹肌中转移核酸的改进方法和用于实施该方法的组合
FR2778858B1 (fr) 1998-05-20 2000-06-16 Oreal Emulsion e/h/e stable et son utilisation comme composition cosmetique et/ou dermatologique
FR2801607B1 (fr) 1999-11-26 2001-12-28 Merial Sas Pneumovirus du canard et vaccins correspondants
US6852705B2 (en) 2000-01-21 2005-02-08 Merial DNA vaccines for farm animals, in particular bovines and porcines
US7179456B2 (en) 2003-04-30 2007-02-20 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Use of parvovirus for brain tumor therapy
RU2354399C2 (ru) 2003-07-24 2009-05-10 Мериал Лимитед Вакцинная композиция и способ индуцирования иммунологического ответа у животного
CN102971417B (zh) 2009-10-14 2016-11-16 俄克拉荷马州大学评议会 自浣熊分离犬细小病毒-2相关病毒
WO2011127316A1 (en) 2010-04-07 2011-10-13 Novartis Ag Method for generating a parvovirus b19 virus-like particle
US20120052082A1 (en) * 2010-04-09 2012-03-01 Zetra Biologicals, LLC Cross-protective influenza vaccine
AU2013295016A1 (en) * 2012-07-24 2015-01-29 Sanofi Pasteur Vaccine compositions for prevention against dengue virus infection
CN103387996B (zh) * 2013-08-19 2015-07-15 长春西诺生物科技有限公司 犬细小病毒病毒样颗粒、其制备方法及应用
CN103409377B (zh) * 2013-08-28 2015-12-23 中国农业科学院兰州兽医研究所 犬细小病毒病毒样颗粒的制备及用途
JP6818748B2 (ja) * 2015-09-29 2021-01-20 ベーリンガー インゲルハイム アニマル ヘルス ユーエスエイ インコーポレイテッド イヌパルボウイルス（ｃｐｖ）ウイルス様粒子（ｖｌｐ）ワクチン及びその使用

Also Published As

Publication number Publication date
CL2018000820A1 (es) 2019-03-01
DK3355915T3 (da) 2024-01-29
BR112018006567A2 (pt) 2018-12-11
FI3355915T3 (fi) 2024-01-12
EP3355915A1 (en) 2018-08-08
CO2018003460A2 (es) 2018-06-20
CA3000352A1 (en) 2017-04-06
MA43016A (fr) 2018-08-08
EP3355915B1 (en) 2023-11-01
EP4286002A2 (en) 2023-12-06
WO2017058521A1 (en) 2017-04-06
US10080798B2 (en) 2018-09-25
US20170087244A1 (en) 2017-03-30
JP2018529718A (ja) 2018-10-11
PT3355915T (pt) 2023-12-19
RS65084B1 (sr) 2024-02-29
SI3355915T1 (sl) 2024-03-29
US10537632B2 (en) 2020-01-21
CN108348594A (zh) 2018-07-31
HRP20231630T1 (hr) 2024-03-15
AU2016332037A1 (en) 2018-05-10
AR106026A1 (es) 2017-12-06
EP4286002A3 (en) 2024-02-28
JP6818748B2 (ja) 2021-01-20
ZA201802117B (en) 2019-01-30
CN108348594B (zh) 2022-09-09
RU2710854C1 (ru) 2020-01-14
PL3355915T3 (pl) 2024-03-25
US20190000965A1 (en) 2019-01-03
AU2016332037B2 (en) 2019-06-27
NZ741875A (en) 2019-08-30
LT3355915T (lt) 2024-01-25

Similar Documents

Publication Publication Date Title
MX2018004016A (es) Vacunas de particulas tipo virus (vlp) contra el parvovirus canino (cpv) y sus usos.
WO2017191258A9 (en) Influenza mrna vaccines
WO2017070620A3 (en) Broad spectrum influenza virus vaccine
MX2016016722A (es) Coronavirus.
MX361893B (es) Vectores recombinantes de herpesvirus 3 galido (mdv serotipo 2) que expresan antigenos de patogenos de aves y sus usos.
WO2016019134A8 (en) Flagellin-based agents and uses including effective vaccination
WO2015195218A8 (en) Polyvalent influenza virus-like particles (vlps) and use as vaccines
PH12019500854A1 (en) Recombinant vectors expressing antigens of avian influenza virus and uses thereof
EP3939604A3 (en) Influenza hemagglutinin protein vaccines
MY189495A (en) Hand, foot, and mouth vaccines and methods of manufacture and use thereof
WO2016210083A3 (en) Inactivated canine influenza vaccines and methods of making and uses thereof
MX2018013340A (es) Combinaciones de vacunas terapeuticas para el vph.
MX2020005584A (es) Vacunacion con particulas de replicon y adyuvante oleoso.
PH12017501100B1 (en) Recombinant swinepox virus and vaccines
SI3518948T1 (sl) Kompozicije in metode za povečanje rasti, širjenja ter onkolitične in imunoterapevtske učinkovitosti onkolitičnih RNA-virusov
MX2018014955A (es) Vacunas atenuadas vivas del virus de la influenza equina.
WO2012058493A3 (en) Recombinant hemagglutinin protein of influenza virus and vaccine containing the same
EP3498850A4 (en) HETEROLOGICAL EXPRESSION CASSETTE, DNA CONSTRUCT AND VACCINE COMPOSITION FOR IMMUNIZATION AGAINST FLAVIVIRUS AND / OR OTHER PATHOGENS
EP3545973A4 (en) COMPOSITION OF VACCINE CONTAINING PARTICLES OF THE HEPATITIS B VIRUS TYPE USED AS AN ADJUVANT
KR102211077B9 (ko) 바이러스 유사 입자를 이용한 슈도-타입 광견병 백신
IL259451B (en) A live virus containing an attenuated dengue virus and a dengue vaccine containing identical antigens